|
Public Act 099-0843 |
HB6333 Enrolled | LRB099 18475 NHT 42851 b |
|
|
AN ACT concerning education.
|
Be it enacted by the People of the State of Illinois,
|
represented in the General Assembly:
|
Section 5. The School Code is amended by changing Section |
22-30 as follows:
|
(105 ILCS 5/22-30)
|
Sec. 22-30. Self-administration and self-carry of asthma |
medication and epinephrine auto-injectors; administration of |
undesignated epinephrine auto-injectors; administration of an |
opioid antagonist ; asthma episode emergency response protocol .
|
(a) For the purpose of this Section only, the following |
terms shall have the meanings set forth below:
|
"Asthma action plan" means a written plan developed with a |
pupil's medical provider to help control the pupil's asthma. |
The goal of an asthma action plan is to reduce or prevent |
flare-ups and emergency department visits through day-to-day |
management and to serve as a student-specific document to be |
referenced in the event of an asthma episode. |
"Asthma episode emergency response protocol" means a |
procedure to provide assistance to a pupil experiencing |
symptoms of wheezing, coughing, shortness of breath, chest |
tightness, or breathing difficulty. |
"Asthma inhaler" means a quick reliever asthma inhaler. |
|
"Epinephrine auto-injector" means a single-use device used |
for the automatic injection of a pre-measured dose of |
epinephrine into the human body.
|
"Asthma medication" means a medicine, prescribed by (i) a |
physician
licensed to practice medicine in all its branches,
|
(ii) a licensed physician assistant with prescriptive |
authority, or (iii) a licensed advanced practice
nurse with |
prescriptive authority
for a pupil that pertains to the pupil's
|
asthma and that has an individual prescription label.
|
"Opioid antagonist" means a drug that binds to opioid |
receptors and blocks or inhibits the effect of opioids acting |
on those receptors, including, but not limited to, naloxone |
hydrochloride or any other similarly acting drug approved by |
the U.S. Food and Drug Administration. |
"School nurse" means a registered nurse working in a school |
with or without licensure endorsed in school nursing. |
"Self-administration" means a pupil's discretionary use of |
his or
her prescribed asthma medication or epinephrine |
auto-injector.
|
"Self-carry" means a pupil's ability to carry his or her |
prescribed asthma medication or epinephrine auto-injector. |
"Standing protocol" may be issued by (i) a physician |
licensed to practice medicine in all its branches, (ii) a |
licensed physician assistant with prescriptive authority, or |
(iii) a licensed advanced practice nurse with prescriptive |
authority . |
|
"Trained personnel" means any school employee or volunteer |
personnel authorized in Sections 10-22.34, 10-22.34a, and |
10-22.34b of this Code who has completed training under |
subsection (g) of this Section to recognize and respond to |
anaphylaxis. |
"Undesignated epinephrine auto-injector" means an |
epinephrine auto-injector prescribed in the name of a school |
district, public school, or nonpublic school. |
(b) A school, whether public or nonpublic, must permit the
|
self-administration and self-carry of asthma
medication by a |
pupil with asthma or the self-administration and self-carry of |
an epinephrine auto-injector by a pupil, provided that:
|
(1) the parents or
guardians of the pupil provide to |
the school (i) written
authorization from the parents or |
guardians for (A) the self-administration and self-carry |
of asthma medication or (B) the self-carry of asthma |
medication or (ii) for (A) the self-administration and |
self-carry of an epinephrine auto-injector or (B) the |
self-carry of an epinephrine auto-injector, written |
authorization from the pupil's physician, physician |
assistant, or advanced practice nurse; and
|
(2) the
parents or guardians of the pupil provide to |
the school (i) the prescription label, which must contain |
the name of the asthma medication, the prescribed dosage, |
and the time at which or circumstances under which the |
asthma medication is to be administered, or (ii) for the |
|
self-administration or self-carry of an epinephrine |
auto-injector, a
written
statement from the pupil's |
physician, physician assistant, or advanced practice
nurse |
containing
the following information:
|
(A) the name and purpose of the epinephrine |
auto-injector;
|
(B) the prescribed dosage; and
|
(C) the time or times at which or the special |
circumstances
under which the epinephrine |
auto-injector is to be administered.
|
The information provided shall be kept on file in the office of |
the school
nurse or,
in the absence of a school nurse, the |
school's administrator.
|
(b-5) A school district, public school, or nonpublic school |
may authorize the provision of a student-specific or |
undesignated epinephrine auto-injector to a student or any |
personnel authorized under a student's Individual Health Care |
Action Plan, Illinois Food Allergy Emergency Action Plan and |
Treatment Authorization Form, or plan pursuant to Section 504 |
of the federal Rehabilitation Act of 1973 to administer an |
epinephrine auto-injector to the student, that meets the |
student's prescription on file. |
(b-10) The school district, public school, or nonpublic |
school may authorize a school nurse or trained personnel to do |
the following: (i) provide an undesignated epinephrine |
auto-injector to a student for self-administration only or any |
|
personnel authorized under a student's Individual Health Care |
Action Plan, Illinois Food Allergy Emergency Action Plan and |
Treatment Authorization Form, or plan pursuant to Section 504 |
of the federal Rehabilitation Act of 1973 to administer to the |
student, that meets the student's prescription on file; (ii) |
administer an undesignated epinephrine auto-injector that |
meets the prescription on file to any student who has an |
Individual Health Care Action Plan, Illinois Food Allergy |
Emergency Action Plan and Treatment Authorization Form, or plan |
pursuant to Section 504 of the federal Rehabilitation Act of |
1973 that authorizes the use of an epinephrine auto-injector; |
(iii) administer an undesignated epinephrine auto-injector to |
any person that the school nurse or trained personnel in good |
faith believes is having an anaphylactic reaction; and (iv) |
administer an opioid antagonist to any person that the school |
nurse or trained personnel in good faith believes is having an |
opioid overdose. |
(c) The school district, public school, or nonpublic school |
must inform the parents or
guardians of the
pupil, in writing, |
that the school district, public school, or nonpublic school |
and its
employees and
agents, including a physician, physician |
assistant, or advanced practice nurse providing standing |
protocol or prescription for school epinephrine |
auto-injectors,
are to incur no liability or professional |
discipline, except for willful and wanton conduct, as a result
|
of any injury arising from the
administration of asthma |
|
medication, an epinephrine auto-injector, or an opioid |
antagonist regardless of whether authorization was given by the |
pupil's parents or guardians or by the pupil's physician, |
physician assistant, or advanced practice nurse. The parents or |
guardians
of the pupil must sign a statement acknowledging that |
the school district, public school,
or nonpublic school and its |
employees and agents are to incur no liability, except for |
willful and wanton
conduct, as a result of any injury arising
|
from the
administration of asthma medication, an epinephrine |
auto-injector, or an opioid antagonist regardless of whether |
authorization was given by the pupil's parents or guardians or |
by the pupil's physician, physician assistant, or advanced |
practice nurse and that the parents or
guardians must indemnify |
and hold harmless the school district, public school, or |
nonpublic
school and
its
employees and agents against any |
claims, except a claim based on willful and
wanton conduct, |
arising out of the
administration of asthma medication, an |
epinephrine auto-injector, or an opioid antagonist regardless |
of whether authorization was given by the pupil's parents or |
guardians or by the pupil's physician, physician assistant, or |
advanced practice nurse. |
(c-5) When a school nurse or trained personnel administers |
an undesignated epinephrine auto-injector to a person whom the |
school nurse or trained personnel in good faith believes is |
having an anaphylactic reaction , or administers an opioid |
antagonist to a person whom the school nurse or trained |
|
personnel in good faith believes is having an opioid overdose, |
notwithstanding the lack of notice to the parents or guardians |
of the pupil or the absence of the parents or guardians signed |
statement acknowledging no liability, except for willful and |
wanton conduct, the school district, public school, or |
nonpublic school and its employees and agents, and a physician, |
a physician assistant, or an advanced practice nurse providing |
standing protocol or prescription for undesignated epinephrine |
auto-injectors, are to incur no liability or professional |
discipline, except for willful and wanton conduct, as a result |
of any injury arising from the use of an undesignated |
epinephrine auto-injector or the use of an opioid antagonist |
regardless of whether authorization was given by the pupil's |
parents or guardians or by the pupil's physician, physician |
assistant, or advanced practice nurse.
|
(d) The permission for self-administration and self-carry |
of asthma medication or the self-administration and self-carry |
of an epinephrine auto-injector is effective
for the school |
year for which it is granted and shall be renewed each
|
subsequent school year upon fulfillment of the requirements of |
this
Section.
|
(e) Provided that the requirements of this Section are |
fulfilled, a
pupil with asthma may self-administer and |
self-carry his or her asthma medication or a pupil may |
self-administer and self-carry an epinephrine auto-injector |
(i) while in
school, (ii) while at a school-sponsored activity, |
|
(iii) while under the
supervision of
school personnel, or (iv) |
before or after normal school activities, such
as while in |
before-school or after-school care on school-operated
|
property.
|
(e-5) Provided that the requirements of this Section are |
fulfilled, a school nurse or trained personnel may administer |
an undesignated epinephrine auto-injector to any person whom |
the school nurse or trained personnel in good faith believes to |
be having an anaphylactic reaction (i) while in school, (ii) |
while at a school-sponsored activity, (iii) while under the |
supervision of school personnel, or (iv) before or after normal |
school activities, such
as while in before-school or |
after-school care on school-operated property. A school nurse |
or trained personnel may carry undesignated epinephrine |
auto-injectors on his or her person while in school or at a |
school-sponsored activity. |
(e-10) Provided that the requirements of this Section are |
fulfilled, a school nurse or trained personnel may administer |
an opioid antagonist to any person whom the school nurse or |
trained personnel in good faith believes to be having an opioid |
overdose (i) while in school, (ii) while at a school-sponsored |
activity, (iii) while under the supervision of school |
personnel, or (iv) before or after normal school activities, |
such as while in before-school or after-school care on |
school-operated property. A school nurse or trained personnel |
may carry an opioid antagonist on their person while in school |
|
or at a school-sponsored activity. |
(f) The school district, public school, or nonpublic school |
may maintain a supply of undesignated epinephrine |
auto-injectors in any secure location where an allergic person |
is most at risk, including, but not limited to, classrooms and |
lunchrooms. A physician, a physician assistant who has been |
delegated prescriptive authority in accordance with Section |
7.5 of the Physician Assistant Practice Act of 1987, or an |
advanced practice nurse who has been delegated prescriptive |
authority in accordance with Section 65-40 of the Nurse |
Practice Act may prescribe undesignated epinephrine |
auto-injectors in the name of the school district, public |
school, or nonpublic school to be maintained for use when |
necessary. Any supply of epinephrine auto-injectors shall be |
maintained in accordance with the manufacturer's instructions. |
The school district, public school, or nonpublic school may |
maintain a supply of an opioid antagonist in any secure |
location where an individual may have an opioid overdose. A |
health care professional who has been delegated prescriptive |
authority for opioid antagonists in accordance with Section |
5-23 of the Alcoholism and Other Drug Abuse and Dependency Act |
may prescribe opioid antagonists in the name of the school |
district, public school, or nonpublic school, to be maintained |
for use when necessary. Any supply of opioid antagonists shall |
be maintained in accordance with the manufacturer's |
instructions. |
|
(f-5) Upon any administration of an epinephrine |
auto-injector, a school district, public school, or nonpublic |
school must immediately activate the EMS system and notify the |
student's parent, guardian, or emergency contact, if known. |
Upon any administration of an opioid antagonist, a school |
district, public school, or nonpublic school must immediately |
activate the EMS system and notify the student's parent, |
guardian, or emergency contact, if known. |
(f-10) Within 24 hours of the administration of an |
undesignated epinephrine auto-injector, a school district, |
public school, or nonpublic school must notify the physician, |
physician assistant, or advanced advance practice nurse who |
provided the standing protocol or prescription for the |
undesignated epinephrine auto-injector of its use. |
Within 24 hours after the administration of an opioid |
antagonist, a school district, public school, or nonpublic |
school must notify the health care professional who provided |
the prescription for the opioid antagonist of its use. |
(g) Prior to the administration of an undesignated |
epinephrine auto-injector, trained personnel must submit to |
their his or her school's administration proof of completion of |
a training curriculum to recognize and respond to anaphylaxis |
that meets the requirements of subsection (h) of this Section. |
Training must be completed annually. Trained personnel must |
also submit to their his or her school's administration proof |
of cardiopulmonary resuscitation and automated external |
|
defibrillator certification. The school district, public |
school, or nonpublic school must maintain records related to |
the training curriculum and trained personnel. |
Prior to the administration of an opioid antagonist, |
trained personnel must submit to their school's administration |
proof of completion of a training curriculum to recognize and |
respond to an opioid overdose, which curriculum must meet the |
requirements of subsection (h-5) of this Section. Training must |
be completed annually. Trained personnel must also submit to |
the school's administration proof of cardiopulmonary |
resuscitation and automated external defibrillator |
certification. The school district, public school, or |
nonpublic school must maintain records relating to the training |
curriculum and the trained personnel. |
(h) A training curriculum to recognize and respond to |
anaphylaxis, including the administration of an undesignated |
epinephrine auto-injector, may be conducted online or in |
person. It must include, but is not limited to: |
(1) how to recognize symptoms of an allergic reaction; |
(2) a review of high-risk areas within the school and |
its related facilities; |
(3) steps to take to prevent exposure to allergens; |
(4) how to respond to an emergency involving an |
allergic reaction; |
(5) how to administer an epinephrine auto-injector; |
(6) how to respond to a student with a known allergy as |
|
well as a student with a previously unknown allergy; |
(7) a test demonstrating competency of the knowledge |
required to recognize anaphylaxis and administer an |
epinephrine auto-injector; and |
(8) other criteria as determined in rules adopted |
pursuant to this Section. |
In consultation with statewide professional organizations |
representing physicians licensed to practice medicine in all of |
its branches, registered nurses, and school nurses, the State |
Board of Education shall make available resource materials |
consistent with criteria in this subsection (h) for educating |
trained personnel to recognize and respond to anaphylaxis. The |
State Board may take into consideration the curriculum on this |
subject developed by other states, as well as any other |
curricular materials suggested by medical experts and other |
groups that work on life-threatening allergy issues. The State |
Board is not required to create new resource materials. The |
State Board shall make these resource materials available on |
its Internet website. |
(h-5) A training curriculum to recognize and respond to an |
opioid overdose, including the administration of an opioid |
antagonist, may be conducted online or in person. The training |
must comply with any training requirements under Section 5-23 |
of the Alcoholism and Other Drug Abuse and Dependency Act and |
the corresponding rules. It must include, but is not limited |
to: |
|
(1) how to recognize symptoms of an opioid overdose; |
(2) information on drug overdose prevention and |
recognition; |
(3) how to perform rescue breathing and resuscitation; |
(4) how to respond to an emergency involving an opioid |
overdose; |
(5) opioid antagonist dosage and administration; |
(6) the importance of calling 911; |
(7) care for the overdose victim after administration |
of the overdose antagonist; |
(8) a test demonstrating competency of the knowledge |
required to recognize an opioid overdose and administer a |
dose of an opioid antagonist; and |
(9) other criteria as determined in rules adopted |
pursuant to this Section. |
(i) Within 3 days after the administration of an |
undesignated epinephrine auto-injector by a school nurse, |
trained personnel, or a student at a school or school-sponsored |
activity, the school must report to the State Board in a form |
and manner prescribed by the State Board the following |
information: |
(1) age and type of person receiving epinephrine |
(student, staff, visitor); |
(2) any previously known diagnosis of a severe allergy; |
(3) trigger that precipitated allergic episode; |
(4) location where symptoms developed; |
|
(5) number of doses administered; |
(6) type of person administering epinephrine (school |
nurse, trained personnel, student); and |
(7) any other information required by the State Board. |
(i-5) Within 3 days after the administration of an opioid |
antagonist by a school nurse or trained personnel, the school |
must report to the State Board, in a form and manner prescribed |
by the State Board, the following information: |
(1) the age and type of person receiving the opioid |
antagonist (student, staff, or visitor); |
(2) the location where symptoms developed; |
(3) the type of person administering the opioid |
antagonist (school nurse or trained personnel); and |
(4) any other information required by the State Board. |
(j) By October 1, 2015 and every year thereafter, the State |
Board shall submit a report to the General Assembly identifying |
the frequency and circumstances of epinephrine administration |
during the preceding academic year. This report shall be |
published on the State Board's Internet website on the date the |
report is delivered to the General Assembly. |
(j-5) Annually, each school district, public school, |
charter school, or nonpublic school shall request an asthma |
action plan from the parents or guardians of a pupil with |
asthma. If provided, the asthma action plan must be kept on |
file in the office of the school nurse or, in the absence of a |
school nurse, the school administrator. Copies of the asthma |
|
action plan may be distributed to appropriate school staff who |
interact with the pupil on a regular basis, and, if applicable, |
may be attached to the pupil's federal Section 504 plan or |
individualized education program plan. |
(j-10) To assist schools with emergency response |
procedures for asthma, the State Board of Education, in |
consultation with statewide professional organizations with |
expertise in asthma management and a statewide organization |
representing school administrators, shall develop a model |
asthma episode emergency response protocol before September 1, |
2016. Each school district, charter school, and nonpublic |
school shall adopt an asthma episode emergency response |
protocol before January 1, 2017 that includes all of the |
components of the State Board's model protocol. |
(j-15) Every 2 years, school personnel who work with pupils |
shall complete an in-person or online training program on the |
management of asthma, the prevention of asthma symptoms, and |
emergency response in the school setting. In consultation with |
statewide professional organizations with expertise in asthma |
management, the State Board of Education shall make available |
resource materials for educating school personnel about asthma |
and emergency response in the school setting. |
On or before October 1, 2016 and every year thereafter, the |
State Board shall submit a report to the General Assembly and |
the Department of Public Health identifying the frequency and |
circumstances of opioid antagonist administration during the |
|
preceding academic year. This report shall be published on the |
State Board's Internet website on the date the report is |
delivered to the General Assembly. |
(k) The State Board may adopt rules necessary to implement |
this Section. |
(Source: P.A. 98-795, eff. 8-1-14; 99-173, eff. 7-29-15; |
99-480, eff. 9-9-15; revised 10-13-15.)
|
Section 99. Effective date. This Act takes effect upon |
becoming law.
|